To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Expert Interview Asthma The U-BIOPRED Study An expert interview with Ian Adcock Professor of Respiratory Cell and Molecular Biology, Faculty of Medicine, National Heart & Lung Institute, Imperial College London, UK Ian Adcock Ian Adcock is Professor of Respiratory Cell and Molecular Biology and Head of the Molecular Cell Biology Group at the National Heart and Lung Institute, Imperial College London, UK. He also holds an honorary research position at the Royal Brompton Hospital, enabling him to translate the basic research activities into the clinical environment. Keywords Severe asthma, adults, multi-omics, systems biology, clinical traits, sub-phenotypes, bioinformatics Disclosure: Ian Adcock was supported by U-BIOPRED. U-BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution (www.imi.europa.eu). We would also like to acknowledge help from the IMI funded eTRIKS project (EU Grant Code No.115446). This is an expert interview piece and as such has not undergone the journal’s standard peer review process. No funding was received for the publication of this article. Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 14 February 2017 Published Online: 26 July 2017 Citation: European Respiratory & Pulmonary Diseases, 2017;3(1):15–6 Corresponding Author: Ian Adcock, Faculty of Medicine, National Heart & Lung Institute, Imperial College London, UK. E: ian.adcock@imperial.ac.uk P rofessor Adcock obtained a degree in biochemistry and physiology from the University of London and later completed a PhD in pharmacology from St Thomas’ Hospital, London, on the role of nuclear receptors on sexual dimorphic patterns in the rat. He performed postdoctoral training at the Medical Research Council (MRC) Brain Metabolism Unit with Professors Tony Harmar and George Fink, and in the Protein Science Laboratory at St Georges’ Hospital with Professor Brian Austen. He joined Professor Peter Barnes at the National Heart and Lung Institute in 1990 to undertake research on the effects of corticosteroids on inflammatory mediators in asthma and chronic obstructive pulmonary disease (COPD). This remains his major research area, along with a long-term interest in the mechanisms underlying relative steroid insensitivity in severe asthma and COPD. Professor Adcock is an internationally recognised scientist in the field of airways disease and inflammation. He has authored and co-authored over 230 scientific articles and has served on the editorial boards of several journals. He has worked as an expert member on national grant- awarding organisations including the UK MRC, the US National Institues of Health (NIH), the Australian National Health and Medical Research Council (NHMRC), the French Agence Nationale de la Recherche (ANR), the Norwegian Research Council and the Medical Research Council of Canada. He has served on the European Respiratory Society (ERS) Council and is currently a member of the ERS Executive Committee and Scientific Programme Committee and Head of the ERS Assembly 5 (Airways Disease). Professor Adcock is a principal investigator in the Medical Research Council/Asthma UK Centre in Allergic Mechanisms of Asthma and in the Wellcome Trust Respiratory Infections Centre. His recent research has been funded by grants from the Medical Research Council, Wellcome Trust, the British Heart Foundation, the Royal Society, the European Union, the Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council and industrial collaborators. He is also a principal investigator in the European consortium Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) on mechanisms of severe asthma that is funded through the Innovative Medicine Initiative of the European Union and European Federation of Pharmaceutical Industries and Associations. Q: Can you tell us a little about the aims of the U-BIOPRED study? U-BIOPRED is a European consortium of over 20 academic institutions, 11 pharmaceutical companies and six patient organisations, funded by the Innovative Medicines Initiative (IMI), whose aim is the better characterisation of severe asthma. It is particularly centered on TOU CH MED ICA L MEDIA 15